Cargando…

Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report

Immune checkpoint inhibitors (ICIs) expanded the therapeutic options for several cancers. However, whether some special groups of patients including those with organ transplantation can receive ICIs remains unclear. In this report we presented an interesting case. A 54-year-old woman underwent kidne...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Didi, Wu, Xinyi, Xie, Congying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187800/
https://www.ncbi.nlm.nih.gov/pubmed/34123796
http://dx.doi.org/10.3389/fonc.2021.646322
_version_ 1783705208836063232
author Chen, Didi
Wu, Xinyi
Xie, Congying
author_facet Chen, Didi
Wu, Xinyi
Xie, Congying
author_sort Chen, Didi
collection PubMed
description Immune checkpoint inhibitors (ICIs) expanded the therapeutic options for several cancers. However, whether some special groups of patients including those with organ transplantation can receive ICIs remains unclear. In this report we presented an interesting case. A 54-year-old woman underwent kidney transplantation, developed metastasis 7 years after operation of the bladder tumor. Her disease progressed after chemotherapy and radiotherapy. Anti-PD-1 immunotherapy was then considered. After two cycles of nivolumab immunotherapy, the patient’s renal function declined rapidly. Acute allograft rejection was considered. There was no significant decrease in creatinine after glucocorticoid pulse therapy. Third course of nivolumab was given, and regularly hemodialysis was simultaneously conducted. Two weeks later, the patient showed left abdominal pain. CT scan revealed a reduction in tumor burden, while enlarged volume of kidney graft. Immunotherapy stopped. Two months after the third course, CT demonstrated a complete remission to immunotherapy. 23 months after the third course, CT showed that the swelling transplanted kidney was smaller than previous, and no recurrence was observed.
format Online
Article
Text
id pubmed-8187800
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81878002021-06-10 Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report Chen, Didi Wu, Xinyi Xie, Congying Front Oncol Oncology Immune checkpoint inhibitors (ICIs) expanded the therapeutic options for several cancers. However, whether some special groups of patients including those with organ transplantation can receive ICIs remains unclear. In this report we presented an interesting case. A 54-year-old woman underwent kidney transplantation, developed metastasis 7 years after operation of the bladder tumor. Her disease progressed after chemotherapy and radiotherapy. Anti-PD-1 immunotherapy was then considered. After two cycles of nivolumab immunotherapy, the patient’s renal function declined rapidly. Acute allograft rejection was considered. There was no significant decrease in creatinine after glucocorticoid pulse therapy. Third course of nivolumab was given, and regularly hemodialysis was simultaneously conducted. Two weeks later, the patient showed left abdominal pain. CT scan revealed a reduction in tumor burden, while enlarged volume of kidney graft. Immunotherapy stopped. Two months after the third course, CT demonstrated a complete remission to immunotherapy. 23 months after the third course, CT showed that the swelling transplanted kidney was smaller than previous, and no recurrence was observed. Frontiers Media S.A. 2021-05-26 /pmc/articles/PMC8187800/ /pubmed/34123796 http://dx.doi.org/10.3389/fonc.2021.646322 Text en Copyright © 2021 Chen, Wu and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Didi
Wu, Xinyi
Xie, Congying
Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
title Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
title_full Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
title_fullStr Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
title_full_unstemmed Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
title_short Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
title_sort nivolumab for metastatic urothelial cancer in a renal allograft recipient with subsequent graft rejection and treatment complete remission: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187800/
https://www.ncbi.nlm.nih.gov/pubmed/34123796
http://dx.doi.org/10.3389/fonc.2021.646322
work_keys_str_mv AT chendidi nivolumabformetastaticurothelialcancerinarenalallograftrecipientwithsubsequentgraftrejectionandtreatmentcompleteremissionacasereport
AT wuxinyi nivolumabformetastaticurothelialcancerinarenalallograftrecipientwithsubsequentgraftrejectionandtreatmentcompleteremissionacasereport
AT xiecongying nivolumabformetastaticurothelialcancerinarenalallograftrecipientwithsubsequentgraftrejectionandtreatmentcompleteremissionacasereport